CoChat
Sign Up
Cited by 2,057

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Smolen, Josef S, Landewé, Robert, Bijlsma, Johannes, Burmester, Gerd, Chatzidionysiou, Katerina, Dougados, Maxime, Nam, Jackie, Ramiro, Sofia, Voshaar, Marieke, van Vollenhoven, Ronald, Aletaha, Daniel, Aringer, Martin, Boers, Maarten, Buckley, Chris D, Buttgereit, Frank, Bykerk, Vivian, Cardiel, Mario, Combe, Bernard, Cutolo, Maurizio, van Eijk-Hustings, Yvonne, Emery, Paul, Finckh, Axel, Gabay, Cem, Gomez-Reino, Juan, Gossec, Laure, Gottenberg, Jacques-Eric, Hazes, Johanna M W, Huizinga, Tom, Jani, Meghna, Karateev, Dmitry, Kouloumas, Marios, Kvien, Tore, Li, Zhanguo, Mariette, Xavier, McInnes, Iain, Mysler, Eduardo, Nash, Peter, Pavelka, Karel, Poór, Gyula, Richez, Christophe, van Riel, Piet, Rubbert-Roth, Andrea, Saag, Kenneth, da Silva, Jose, Stamm, Tanja, Takeuchi, Tsutomu, Westhovens, René, de Wit, Maarten, van der Heijde, Désirée·2017·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2016-210715
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2016-210715

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • According to the 2016 EULAR recommendations, IL-6 pathway inhibitors may have some advantages compared with other biologics in patients who cannot use conventional synthetic DMARDs as co-medications.

    “according to the 2016 European League Against Rheumatism (EULAR) updated recommendations for the management of RA, IL-6 pathway inhibitors may have some advantages compared with other biologics in patients who cannot use conventional synthetic DMARDs as co-medications (Smolen et al., 2017”

    From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Smolen et al., 2017

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 179

  1. Wilske, 1990, Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis, J Rheumatol, 17, 4
  2. McCarty, 1990, Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians, J Rheumatol, 17, 1117
  3. Weinblatt, 1995, Efficacy of methotrexate in rheumatoid arthritis, Br J Rheumatol, 34, 43, 10.1093/rheumatology/XXXIV.suppl_2.43 · DOI
  4. Visser, 2009, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, 68, 1094, 10.1136/ard.2008.092668 · DOI
  5. van der Heide, 1996, The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial, Ann Intern Med, 124, 699, 10.7326/0003-4819-124-8-199604150-00001 · DOI
  6. Huizinga, 2002, Criteria for early rheumatoid arthritis: from Bayes’ law revisited to new thoughts on pathogenesis, Arthritis Rheum, 46, 1155, 10.1002/art.10195 · DOI
  7. van der Horst-Bruinsma, 1998, Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care, Br J Rheumatol, 37, 1084, 10.1093/rheumatology/37.10.1084 · DOI
  8. Emery, 1991, Why early arthritis clinics?, Br J Rheumatol, 30, 241, 10.1093/rheumatology/30.4.241 · DOI
  9. Aletaha, 2005, The need for new classification criteria for rheumatoid arthritis, Arthritis Rheum, 52, 3333, 10.1002/art.21410 · DOI
  10. Emery, 1995, Early rheumatoid arthritis: time to aim for remission?, Ann Rheum Dis, 54, 944, 10.1136/ard.54.12.944 · DOI
  11. Smolen, 2014, Proposal for a new nomenclature of disease-modifying antirheumatic drugs, Ann Rheum Dis, 73, 3, 10.1136/annrheumdis-2013-204317 · DOI
  12. Smolen, 2016, Rheumatoid arthritis, Lancet, 388, 2023, 10.1016/S0140-6736(16)30173-8 · DOI
  13. Aletaha, 2010, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 69, 1580, 10.1136/ard.2010.138461 · DOI
  14. Smolen, 2016, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, 75, 3, 10.1136/annrheumdis-2015-207524 · DOI
  15. Smolen, 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 492, 10.1136/annrheumdis-2013-204573 · DOI
  16. Singh, 2016, 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), 68, 1, 10.1002/acr.22783 · DOI
  17. van der Heijde, 1993, Development of a disease activity score based on judgment in clinical practice by rheumatologists, J Rheumatol, 20, 579
  18. Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107 · DOI
  19. Smolen, 2003, A Simplified disease activity index for rheumatoid arthritis for use in clinical practice, Rheumatology (Oxford), 42, 244, 10.1093/rheumatology/keg072 · DOI
  20. Aletaha, 2005, Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score, Arthritis Res, 7, R796, 10.1186/ar1740 · DOI
  21. Felson, 2011, American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, Ann Rheum Dis, 70, 404, 10.1136/ard.2011.149765 · DOI
  22. Kavanaugh, 2013, Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study, Ann Rheum Dis, 72, 64, 10.1136/annrheumdis-2011-201247 · DOI
  23. van der Heijde, 2012, Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?, Ann Rheum Dis, 71, i89, 10.1136/annrheumdis-2011-200797 · DOI
  24. Radner, 2014, Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs, Arthritis Res Ther, 16, R56, 10.1186/ar4491 · DOI
  25. Linde, 2010, Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?, J Rheumatol, 37, 285, 10.3899/jrheum.090898 · DOI
  26. Provan, 2011, Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study, Ann Rheum Dis, 70, 812, 10.1136/ard.2010.141523 · DOI
  27. Thiele, 2013, Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis, Ann Rheum Dis, 72, 1194, 10.1136/annrheumdis-2012-201821 · DOI
  28. Bruynesteyn, 2004, Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months’ follow up, Ann Rheum Dis, 63, 1413, 10.1136/ard.2003.014043 · DOI
  29. Cohen, 2008, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis Rheum, 58, 1299, 10.1002/art.23417 · DOI
  30. Aletaha, 2016, Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point, Ann Rheum Dis, 75, 1479, 10.1136/annrheumdis-2015-208324 · DOI
  31. van der Heijde, 2015, 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations, Ann Rheum Dis, 74, 8, 10.1136/annrheumdis-2014-206350 · DOI · Paper page
  32. Ramiro, 2014, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 529, 10.1136/annrheumdis-2013-204575 · DOI
  33. Nam, 2014, Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 73, 516, 10.1136/annrheumdis-2013-204577 · DOI
  34. Gaujoux-Viala, 2014, Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 510, 10.1136/annrheumdis-2013-204588 · DOI
  35. Cardiel, 2014, Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis, Reumatol Clin, 10, 227, 10.1016/j.reuma.2013.10.006 · DOI
  36. Wollenhaupt, 2013, The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint, Z Rheumatol, 72, 6, 10.1007/s00393-012-1093-6 · DOI
  37. Brenol, 2015, Proper management of rheumatoid arthritis in Latin America. What the guidelines say?, Clin Rheumatol, 34, S51, 10.1007/s10067-015-3016-9 · DOI
  38. Lau, 2015, APLAR rheumatoid arthritis treatment recommendations, Int J Rheum Dis, 18, 685, 10.1111/1756-185X.12754 · DOI
  39. Gaujoux-Viala, 2014, Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis, Joint Bone Spine, 81, 287, 10.1016/j.jbspin.2014.05.002 · DOI
  40. Bykerk, 2012, Emerging issues in pharmacological management of rheumatoid arthritis: results of a national needs assessment survey identifying practice variations for the development of Canadian Rheumatology Association clinical practice recommendations, J Rheumatol, 39, 1555, 10.3899/jrheum.110208 · DOI
  41. Dougados, 2004, EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees, Ann Rheum Dis, 63, 1172, 10.1136/ard.2004.023697 · DOI
  42. Brouwers, 2010, AGREE II: advancing guideline development, reporting and evaluation in health care, CMAJ, 182, E839, 10.1503/cmaj.090449 · DOI · Paper page
  43. Guyatt, 2008, Incorporating considerations of resources use into grading recommendations, BMJ, 336, 1170, 10.1136/bmj.39504.506319.80 · DOI
  44. Schoels, 2010, Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 69, 995, 10.1136/ard.2009.126714 · DOI
  45. Dörner, 2016, The changing landscape of biosimilars in rheumatology, Ann Rheum Dis, 75, 974, 10.1136/annrheumdis-2016-209166 · DOI
  46. OCEBM Levels of Evidence Working Group, Oxford Centre for Evidence-Based Medicine. The Oxford 2011 Levels of Evidence. 2011. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
  47. Ramiro, 2016, SLR on safety aspects of DMARDs to inform the EULAR RA management task force, Ann Rheum Dis
  48. Nam, 2016, SLR on bDMARDs to inform the EULAR RA management task force, Ann Rheum Dis
  49. Chatzidionysiou, 2016, SLR on csDMARDs to inform the EULAR RA management task force 2016, Ann Rheum Dis
  50. Peters, 2010, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, 69, 325, 10.1136/ard.2009.113696 · DOI · Paper page
  51. van der Goes, 2010, Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice, Ann Rheum Dis, 69, 1913, 10.1136/ard.2009.124958 · DOI
  52. Hoes, 2007, EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis, 66, 1560, 10.1136/ard.2007.072157 · DOI
  53. van Assen, 2011, EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 70, 414, 10.1136/ard.2010.137216 · DOI
  54. Strehl, 2016, Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force, Ann Rheum Dis, 75, 952, 10.1136/annrheumdis-2015-208916 · DOI
  55. Baillet, 2016, Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative, Ann Rheum Dis, 75, 965, 10.1136/annrheumdis-2016-209233 · DOI
  56. Furst, 2013, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012, Ann Rheum Dis, 72, ii2, 10.1136/annrheumdis-2013-203348 · DOI
  57. Buch, 2011, Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis, Ann Rheum Dis, 70, 909, 10.1136/ard.2010.144998 · DOI
  58. Pereira, 2015, Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy, Drug Dev Res, 76, 419, 10.1002/ddr.21285 · DOI
  59. Smolen, 2013, Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, Ann Rheum Dis, 72, 482, 10.1136/annrheumdis-2012-202469 · DOI
  60. Strangfeld, 2011, Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?, Ann Rheum Dis, 70, 1914, 10.1136/ard.2011.151043 · DOI
  61. Zink, 2014, Evaluation of the RABBIT Risk Score for serious infections, Ann Rheum Dis, 73, 1673, 10.1136/annrheumdis-2013-203341 · DOI
  62. St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568 · DOI
  63. Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 · DOI · Paper page
  64. Breedveld, 2006, Arthritis Rheum, 54, 26, 10.1002/art.21519 · DOI
  65. Smolen, 2014, Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial, Lancet, 383, 321, 10.1016/S0140-6736(13)61751-1 · DOI
  66. Vastesaeger, 2009, A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis, Rheumatology (Oxford), 48, 1114, 10.1093/rheumatology/kep155 · DOI
  67. Combe, 2016, 2016 update of the EULAR recommendations for the management of early arthritis, Ann Rheum Dis, 10.1136/annrheumdis-2016-eular.6370 · DOI
  68. Stoffer, 2014, Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project, Ann Rheum Dis, 73, 902, 10.1136/annrheumdis-2013-203743 · DOI
  69. Navarro-Compán, 2015, Quality indicators in rheumatoid arthritis: results from the METEOR database, Rheumatology (Oxford), 54, 1630, 10.1093/rheumatology/kev108 · DOI
  70. Widdifield, 2011, Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective, Arthritis Care Res (Hoboken), 63, 53, 10.1002/acr.20304 · DOI
  71. Memel, 2003, General practitioner and specialist care: the perceptions of people with rheumatoid arthritis, Prim Health Care Res Dev, 4, 29, 10.1191/1463423603pc120oa · DOI
  72. Robinson, 2010, Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals, J Clin Rheumatol, 16, 267, 10.1097/RHU.0b013e3181eeb499 · DOI
  73. Kyburz, 2011, The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study, Rheumatology (Oxford), 50, 1106, 10.1093/rheumatology/keq424 · DOI
  74. Feldman, 2013, Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery?, Rheumatology (Oxford), 52, 452, 10.1093/rheumatology/kes231 · DOI
  75. Nasonov, 2015, Does Russia need a treat-to-target initiative?, Rheumatology (Oxford), 54, 381, 10.1093/rheumatology/keu156 · DOI
  76. Smolen, 2015, Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges, Nat Rev Rheumatol, 11, 276, 10.1038/nrrheum.2015.8 · DOI
  77. Cader, 2011, Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort, Ann Rheum Dis, 70, 949, 10.1136/ard.2010.143560 · DOI
  78. Radner, 2014, Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review, Ann Rheum Dis, 73, 114, 10.1136/annrheumdis-2013-203284 · DOI
  79. van Aken, 2004, Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis, Ann Rheum Dis, 63, 274, 10.1136/ard.2003.010298 · DOI
  80. Nell, 2004, Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis, Rheumatology (Oxford), 43, 906, 10.1093/rheumatology/keh199 · DOI
  81. Moura, 2015, Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study, Arthritis Res Ther, 17, 197, 10.1186/s13075-015-0713-3 · DOI
  82. Machold, 2010, The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis, Ann Rheum Dis, 69, 495, 10.1136/ard.2009.122473 · DOI
  83. Verstappen, 2010, Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial, Ann Rheum Dis, 69, 503, 10.1136/ard.2009.119149 · DOI
  84. Smolen, 2010, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, 69, 964, 10.1136/ard.2009.126532 · DOI
  85. Klarenbeek, 2011, The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study, Ann Rheum Dis, 70, 1039, 10.1136/ard.2010.141234 · DOI
  86. Aletaha, 2007, Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients, Arthritis Rheum, 56, 3226, 10.1002/art.22943 · DOI
  87. Schipper, 2010, Time to achieve remission determines time to be in remission, Arthritis Res Ther, 12, R97, 10.1186/ar3027 · DOI
  88. Ranganath, 2015, Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy, Arthritis Care Res (Hoboken), 67, 929, 10.1002/acr.22541 · DOI
  89. Sakellariou, 2013, In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis, Ann Rheum Dis, 72, 245, 10.1136/annrheumdis-2012-201817 · DOI
  90. Genovese, 2016, Baricitinib in patients with refractory rheumatoid arthritis, N Engl J Med, 374, 1243, 10.1056/NEJMoa1507247 · DOI
  91. Gabay, 2013, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial, Lancet, 381, 1541, 10.1016/S0140-6736(13)60250-0 · DOI · Paper page
  92. Smolen, 2011, Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants, Arthritis Rheum, 63, 43, 10.1002/art.27740 · DOI
  93. Fleischmann, 2015, How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?, Ann Rheum Dis, 74, 1132, 10.1136/annrheumdis-2013-204920 · DOI
  94. Dale, 2016, Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial, Ann Rheum Dis, 75, 1043, 10.1136/annrheumdis-2015-208941 · DOI
  95. Haavardsholm, 2016, Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial, BMJ, 354, i4205, 10.1136/bmj.i4205 · DOI
  96. Fleischmann, 2012, Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis, N Engl J Med, 367, 495, 10.1056/NEJMoa1109071 · DOI
  97. Curtis, 2012, Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year, Arthritis Care Res (Hoboken), 64, 658, 10.1002/acr.21600 · DOI
  98. van der Heijde, 2012, Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial, J Rheumatol, 39, 1326, 10.3899/jrheum.111171 · DOI
  99. Smolen, 2015, Arthritis Res Ther, 17, 157, 10.1186/s13075-015-0671-9 · DOI
  100. Li, 2016, High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): a multicenter randomized clinical trial, Medicine (Baltimore), 95, e3968, 10.1097/MD.0000000000003968 · DOI
  101. Choi, 2002, Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, Lancet, 359, 1173, 10.1016/S0140-6736(02)08213-2 · DOI
  102. Wasko, 2013, Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis, Arthritis Rheum, 65, 334, 10.1002/art.37723 · DOI
  103. Emery, 2017, Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study, Ann Rheum Dis, 76, 96, 10.1136/annrheumdis-2015-209057 · DOI
  104. Atsumi, 2016, The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression, Ann Rheum Dis, 75, 75, 10.1136/annrheumdis-2015-207511 · DOI
  105. Mottonen, 1999, Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group, Lancet, 353, 1568, 10.1016/S0140-6736(98)08513-4 · DOI
  106. O'Dell, 1996, Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications, N Engl J Med, 334, 1287, 10.1056/NEJM199605163342002 · DOI
  107. Moreland, 2012, A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial, Arthritis Rheum, 64, 2824, 10.1002/art.34498 · DOI
  108. O'Dell, 2013, Therapies for active rheumatoid arthritis after methotrexate failure, N Engl J Med, 369, 307, 10.1056/NEJMoa1303006 · DOI
  109. van Vollenhoven, 2012, Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial, Lancet, 379, 1712, 10.1016/S0140-6736(12)60027-0 · DOI
  110. de Jong, 2014, Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial, Ann Rheum Dis, 73, 1331, 10.1136/annrheumdis-2013-204788 · DOI
  111. Verschueren, 2015, Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial, Ann Rheum Dis, 74, 27, 10.1136/annrheumdis-2014-205489 · DOI
  112. Goekoop-Ruiterman, 2007, Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial, Ann Intern Med, 146, 406, 10.7326/0003-4819-146-6-200703200-00005 · DOI
  113. Smolen, 2005, Superior efficacy of combination therapy for rheumatoid arthritis. Fact or fiction?, Arthritis Rheum, 52, 2975, 10.1002/art.21293 · DOI
  114. Landewé, 2014, Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example, Ann Rheum Dis, 73, 1755, 10.1136/annrheumdis-2014-205821 · DOI
  115. Verschueren, 2017, Ann Rheum Dis
  116. Singh, 2012, 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), 64, 625, 10.1002/acr.21641 · DOI
  117. Cutolo, 2013, Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen, Rheumatology (Oxford), 52, 1132, 10.1093/rheumatology/kes321 · DOI
  118. Gaujoux-Viala, 2010, Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 69, 1004, 10.1136/ard.2009.127225 · DOI
  119. Emery, 2000, A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis, Rheumatology (Oxford), 39, 655, 10.1093/rheumatology/39.6.655 · DOI
  120. Götestam Skorpen, 2016, The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation, Ann Rheum Dis, 75, 795, 10.1136/annrheumdis-2015-208840 · DOI
  121. Rau, 2002, Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients, Rheumatology (Oxford), 41, 196, 10.1093/rheumatology/41.2.196 · DOI
  122. Lehman, 2005, A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study, Arthritis Rheum, 52, 1360, 10.1002/art.21018 · DOI
  123. Katz, 2011, Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action, Curr Opin Rheumatol, 23, 278, 10.1097/BOR.0b013e32834456bf · DOI
  124. Hage, 2014, A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role, Ther Adv Endocrinol Metab, 5, 77, 10.1177/2042018814547204 · DOI
  125. Sharma, 2016, Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients, J Am Heart Assoc, 5, e002867, 10.1161/JAHA.115.002867 · DOI
  126. Van der Heijde, 1990, Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up, Lancet, 335, 539, 10.1016/0140-6736(90)90771-V · DOI
  127. Strangfeld, 2009, Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide, Ann Rheum Dis, 68, 1856, 10.1136/ard.2008.098467 · DOI
  128. De Stefano, 2010, Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha, Clin Rheumatol, 29, 517, 10.1007/s10067-009-1349-y · DOI
  129. Burmester, 2007, Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial, Ann Rheum Dis, 66, 732, 10.1136/ard.2006.066761 · DOI
  130. Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, 3381, 10.1002/art.21405 · DOI
  131. Nam, 2014, Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study), Ann Rheum Dis, 73, 75, 10.1136/annrheumdis-2013-203440 · DOI
  132. Buttgereit, 2002, Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology, Ann Rheum Dis, 61, 718, 10.1136/ard.61.8.718 · DOI · Paper page
  133. Listing, 2015, Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab, Ann Rheum Dis, 74, 415, 10.1136/annrheumdis-2013-204021 · DOI · Paper page
  134. Lahiri, 2015, Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis, Best Pract Res Clin Rheumatol, 29, 290, 10.1016/j.berh.2015.05.009 · DOI
  135. van Sijl, 2014, Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study, PLoS ONE, 9, e87965, 10.1371/journal.pone.0087965 · DOI
  136. del Rincón, 2014, Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis, Arthritis Rheumatol, 66, 264, 10.1002/art.38210 · DOI · Paper page
  137. Choy, 2005, A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs, Ann Rheum Dis, 64, 1288, 10.1136/ard.2004.030908 · DOI
  138. Taylor, 2015, Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study [Abstract], Arthritis Rheum, 67, L2
  139. Yoo, 2017, Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study, Ann Rheum Dis, 76, 355, 10.1136/annrheumdis-2015-208786 · DOI
  140. Choe, 2017, A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis, 76, 58, 10.1136/annrheumdis-2015-207764 · DOI
  141. Emery, 2017, A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis, 76, 51, 10.1136/annrheumdis-2015-207588 · DOI
  142. Schoels, 2012, Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis, Ann Rheum Dis, 71, 1303, 10.1136/annrheumdis-2011-200490 · DOI
  143. Porter, 2016, Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial, Lancet, 388, 239, 10.1016/S0140-6736(16)00380-9 · DOI
  144. Weinblatt, 2013, Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study, Arthritis Rheum, 65, 28, 10.1002/art.37711 · DOI
  145. Coleman, 2016, Role of rituximab and rituximab biosimilars in diffuse large B-cell lymphoma, Clin Lymphoma Myeloma Leuk, 16, 175, 10.1016/j.clml.2016.01.004 · DOI
  146. Emery, 2014, Sustained remission with etanercept tapering in early rheumatoid arthritis, N Engl J Med, 371, 1781, 10.1056/NEJMoa1316133 · DOI
  147. Detert, 2013, Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study, Ann Rheum Dis, 72, 844, 10.1136/annrheumdis-2012-201612 · DOI
  148. Bijlsma, 2016, Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial, Lancet, 388, 343, 10.1016/S0140-6736(16)30363-4 · DOI
  149. Bejarano, 2010, Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis, Rheumatology (Oxford), 49, 1971, 10.1093/rheumatology/keq194 · DOI
  150. Burmester, 2016, Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial, Ann Rheum Dis, 75, 1081, 10.1136/annrheumdis-2015-207628 · DOI · Paper page
  151. Kaneko, 2016, Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study), Ann Rheum Dis, 75, 1917, 10.1136/annrheumdis-2015-208426 · DOI · Paper page
  152. Dougados, 2014, Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study, Ann Rheum Dis, 73, 803, 10.1136/annrheumdis-2013-204761 · DOI
  153. Fleischmann, 2015, Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results [abstract], Arhritis Rheum, 67
  154. Lee, 2012, Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-nave patients with rheumatoid arthritis, Arthritis Rheum, 64, S1049
  155. Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis, 69, 88, 10.1136/ard.2008.105197 · DOI · Paper page
  156. Emery, 2015, Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period, Ann Rheum Dis, 74, 19, 10.1136/annrheumdis-2014-206106 · DOI
  157. Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W · DOI
  158. Burmester, 2015, Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial, Ann Rheum Dis, 74, 1037, 10.1136/annrheumdis-2013-204769 · DOI
  159. Smolen, 2016, Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study, Lancet, 388, 2763, 10.1016/S0140-6736(16)31651-8 · DOI
  160. Torrente-Segarra, 2016, VARIAR study: assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist, Reumatol Clin, 12, 319, 10.1016/j.reuma.2015.11.019 · DOI
  161. Manders, 2015, Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial, Arthritis Res Ther, 17, 134, 10.1186/s13075-015-0630-5 · DOI
  162. Emery, 2013, Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study, Ann Rheum Dis, 72, 399
  163. Smolen, 2015, Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial, Ann Rheum Dis, 74, 843, 10.1136/annrheumdis-2013-204632 · DOI
  164. Tanaka, 2013, Discontinuation of biologics in patients with rheumatoid arthritis, Clin Exp Rheumatol, 31, 522
  165. Schett, 2016, Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions, Ann Rheum Dis, 75, 1428, 10.1136/annrheumdis-2016-209201 · DOI
  166. Fleischmann, 2016, Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab, Arthritis Rheumatol, 68, 2083, 10.1002/art.39714 · DOI
  167. Dixon, 2012, Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis, Ann Rheum Dis, 71, 1128, 10.1136/annrheumdis-2011-200702 · DOI
  168. Hazlewood, 2016, Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis, BMJ, 353, i1777, 10.1136/bmj.i1777 · DOI
  169. Katchamart, 2010, Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis, Cochrane Database Syst Rev, CD008495
  170. Smolen, 2009, Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor-blockade, Ann Rheum Dis, 68, 823, 10.1136/ard.2008.090019 · DOI
  171. Smolen, 2006, Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab: results from the ASPIRE trial, Arthritis Rheum, 54, 702, 10.1002/art.21678 · DOI
  172. van Leeuwen, 1997, Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system, J Rheumatol, 24, 20
  173. Van der Heijde, 1992, Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients, Br J Rheumatol, 31, 519, 10.1093/rheumatology/31.8.519 · DOI
  174. Scott, 1987, Long-term outcome of treating rheumatoid arthritis: results after 20 years, Lancet, 1, 1108, 10.1016/S0140-6736(87)91672-2 · DOI
  175. Visser, 2010, A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study, Ann Rheum Dis, 69, 1333, 10.1136/ard.2009.121160 · DOI
  176. Kiely, 2011, Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN), Rheumatology (Oxford), 50, 926, 10.1093/rheumatology/keq406 · DOI
  177. Duru, 2013, EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis, 72, 1905, 10.1136/annrheumdis-2013-203249 · DOI
  178. Fransen, 2005, The Disease Activity Score and the EULAR response criteria, Clin Exp Rheumatol, 23, S93
  179. Aletaha, 2005, Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states, Arthritis Rheum, 52, 2625, 10.1002/art.21235 · DOI

Cited by

Sorted by citations

Metadata

Authors
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., Aletaha, D., Aringer, M., Boers, M., Buckley, C. D., Buttgereit, F., Bykerk, V., Cardiel, M., Combe, B., Cutolo, M., van Eijk-Hustings, Y., Emery, P., Finckh, A., Gabay, C., Gomez-Reino, J., Gossec, L., Gottenberg, J.-E., Hazes, J. M. W., Huizinga, T., Jani, M., Karateev, D., Kouloumas, M., Kvien, T., Li, Z., Mariette, X., McInnes, I., Mysler, E., Nash, P., Pavelka, K., Poór, G., Richez, C., van Riel, P., Rubbert-Roth, A., Saag, K., da Silva, J., Stamm, T., Takeuchi, T., Westhovens, R., de Wit, M., & van der Heijde, D.
ORCID
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2017-06
Volume
76
Issue
6
Pages
960-977
ISSN
0003-4967
DOI
10.1136/annrheumdis-2016-210715
Cited by
2,057
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review